EP 3429634 A1 20190123 - A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION
Title (en)
A METHOD OF ENGINEERING PRODRUG-SPECIFIC HYPERSENSITIVE T-CELLS FOR IMMUNOTHERAPY BY GENE EXPRESSION
Title (de)
VERFAHREN ZUM ENGINEERING VON PRODRUG-SPEZIFISCHEN ÜBEREMPFINDLICHEN T-ZELLEN ZUR IMMUNTHERAPIE DURCH GENEXPRESSION
Title (fr)
MÉTHODE DE MISE AU POINT PAR GÉNIE GÉNÉTIQUE DE LYMPHOCYTES T HYPERSENSIBLES À UN PROMÉDICAMENT SPÉCIFIQUE POUR UNE IMMUNOTHÉRAPIE PAR EXPRESSION GÉNIQUE
Publication
Application
Priority
- DK PA201670233 A 20160415
- EP 2017058923 W 20170413
Abstract (en)
[origin: WO2017178586A1] The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.
IPC 8 full level
A61K 48/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 5/078 (2010.01); C12N 5/0783 (2010.01)
CPC (source: EP US)
A61K 35/17 (2013.01 - US); A61K 39/4611 (2023.05 - EP); A61K 39/4631 (2023.05 - EP); A61K 39/4644 (2023.05 - EP); C07K 14/7051 (2013.01 - US); C12N 5/0636 (2013.01 - EP US); C12N 15/85 (2013.01 - US); A61K 45/06 (2013.01 - US); C07K 14/7051 (2013.01 - EP); C07K 2319/03 (2013.01 - EP); C12N 2015/8518 (2013.01 - US); C12N 2510/00 (2013.01 - EP US); C12Y 305/04005 (2013.01 - US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017178586 A1 20171019; EP 3429634 A1 20190123; US 2019328783 A1 20191031
DOCDB simple family (application)
EP 2017058923 W 20170413; EP 17718500 A 20170413; US 201716092414 A 20170413